MoonLake Immunotherapeutics (MLTX) Proxy filing summary

Voting matters and shareholder proposals

• Election of Class I director nominee Spike Loy to serve until the 2029 Annual General Meeting of Shareholders and until a successor is elected and qualified.

• Ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the year ending December 31, 2026.

• Advisory approval of the compensation of named executive officers.

• Approval of an amendment and restatement of the 2022 Equity Incentive Plan.

• Other business may be addressed as properly brought before the meeting or any adjournments.

Board of directors and corporate governance

• Shareholders are asked to elect one Class I director nominee, Spike Loy, for a term ending in 2029.

Executive compensation and say-on-pay

• Shareholders will vote on a non-binding, advisory basis to approve the compensation of named executive officers.

• Proposed amendment and restatement of the 2022 Equity Incentive Plan is subject to shareholder approval.